[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Roslyn J. Francis, Andrew D. Redfern

Research output: Contribution to journalArticle

9 Citations (Scopus)

Fingerprint Dive into the research topics of '[<sup>177</sup>Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences